Clinical trials: Depressive Disorder, completed
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Low Mood, Depressive Symptoms
The Effects of Bifidobacterium Longum 1714® in a Population With Low Mood
A randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of 8 weeks of supplementation with Bifidobacterium longum 1714® strain on Beck's Depression Inventory-II Score in adults who experience low mood.
- Trial name
- NCT04925440
- Testing
- Bifidobacterium longum 1714® strain
- Where
- Ireland
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- PrecisionBiotics Group Ltd.
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression
Major Depressive Disorder (MDD)
The purpose of this study is to assess the effectiveness of systematic screening for depression in high-risk patient participants in everyday clinical practice.
- Trial name
- NCT01662817
- Testing
- Intervention, Control
- Where
- Spain
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fasting conditions.
- Trial name
- NCT00913718
- Testing
- Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Depressive Disorder, Major
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
- Trial name
- NCT00733980
- Testing
- GSK561679
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Depression
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
- Trial name
- NCT01396252
- Testing
- BMS-820836
- Where
- Japan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.